Tito Roccia
About
Tito Roccia is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Tito Roccia has authored 25 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 13 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Tito Roccia's work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (10 papers) and CAR-T cell therapy research (8 papers). Tito Roccia is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (10 papers) and CAR-T cell therapy research (8 papers). Tito Roccia collaborates with scholars based in United States, Belgium and United Kingdom. Tito Roccia's co-authors include Erika Biral, Maria Grazia Roncarolo, Sarah Marktel, Barbara Cappelli, Robert Chiesa, Fabio Ciceri, Alessandra Biffi, Marco Fossati, Arlene O. Siefker‐Radtke and Yohann Loriot and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
In The Last Decade
Tito Roccia
24 papers receiving 149 citations
Peers
Tito Roccia
Ramdane Belhocine France
Victoria Gutgarts United States
Ally Speight United Kingdom
Sara Varea Spain
Keith Sibson United Kingdom
A Urbano Ispizua Spain
Caitrin Fretham United States
Mirjam Fechter Netherlands
Machiko Kusuda Japan
Zefarina Zulkafli Malaysia
Citations per year, relative to Tito Roccia Tito Roccia (= 1×)
peers
Ramdane Belhocine
Countries citing papers authored by Tito Roccia
Since
Specialization
Citations
This map shows the geographic impact of Tito Roccia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tito Roccia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tito Roccia more than expected).
Fields of papers citing papers by Tito Roccia
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tito Roccia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tito Roccia. The network helps show where Tito Roccia may publish in the future.
Co-authorship network of co-authors of Tito Roccia
This figure shows the co-authorship network connecting the top 25 collaborators of Tito Roccia. A scholar is included among the top collaborators of Tito Roccia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tito Roccia. Tito Roccia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Khan, Abdullah, Glenn S. Kroog, Tito Roccia, et al.. (2025). Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA×CD3 Bispecific Antibody: A Case Report. eJHaem. 6(6). e70168–e70168.
2.
Jagannath, Sundar, Hans C. Lee, Joshua Richter, et al.. (2025). Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 43(16_suppl). 7531–7531.
3.
Jagannath, Sundar, Hans C. Lee, Joshua Richter, et al.. (2024). Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7560–7560.
4.
Zonder, Jeffrey A., Hans C. Lee, Joshua Richter, et al.. (2024). P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S267–S267.
5.
Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157.
6.
Dimopoulos, Meletios Α., Pieter Sonneveld, Salomon Manier, et al.. (2024). Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. BMC Cancer. 24(1). 541–541.
7.
Mateos, María‐Victoria, Katja Weisel, Joris Diels, et al.. (2023). Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study. Clinical Lymphoma Myeloma & Leukemia. 24(4). 224–231.e2.
8.
Einsele, Hermann, Adam D. Cohen, Michel Delforge, et al.. (2022). Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.. Journal of Clinical Oncology. 40(16_suppl). 8020–8020.
9.
Hillengaß, Jens, Adam D. Cohen, Michel Delforge, et al.. (2022). P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA. HemaSphere. 6. 849–850.
10.
Agha, Mounzer, Adam D. Cohen, Yaël C. Cohen, et al.. (2022). MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy. Clinical Lymphoma Myeloma & Leukemia. 22. S408–S409.
11.
Einsele, Hermann, Michel Delforge, Hartmut Goldschmidt, et al.. (2022). OAB-045: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A. Clinical Lymphoma Myeloma & Leukemia. 22. S27–S28.
12.
Hillengaß, Jens, Adam D. Cohen, Michel Delforge, et al.. (2022). MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT). Clinical Lymphoma Myeloma & Leukemia. 22. S411–S411.
13.
Delforge, Michel, Philippe Moreau, Hermann Einsele, et al.. (2022). Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. Journal of Clinical Oncology. 40(16_suppl). 8030–8030.
14.
Einsele, Hermann, Philippe Moreau, Valerio De Stefano, et al.. (2022). Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. Journal of Clinical Oncology. 40(16_suppl). 8031–8031.
15.
Caplan, Arthur L., et al.. (2018). A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC). Therapeutic Innovation & Regulatory Science. 53(2). 243–248.
16.
Loriot, Yohann, Andrea Necchi, S.H. Park, et al.. (2018). Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. Annals of Oncology. 29. viii327–viii328.
17.
Cappelli, Barbara, Robert Chiesa, Alessandra Biffi, et al.. (2009). Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. British Journal of Haematology. 147(4). 554–560.
18.
Chiesa, Robert, Barbara Cappelli, Roberto Crocchiolo, et al.. (2009). Unpredictability of Intravenous Busulfan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation for Advanced Beta Thalassemia: Limited Toxicity with a Dose-Adjustment Policy. Biology of Blood and Marrow Transplantation. 16(5). 622–628.
19.
Biral, Erika, Robert Chiesa, Barbara Cappelli, et al.. (2008). Multiple BM harvests in pediatric donors for thalassemic siblings: safety, efficacy and ethical issues. Bone Marrow Transplantation. 42(6). 379–384.
20.
Marktel, Sarah, Robert Chiesa, Barbara Cappelli, et al.. (2008). Optimal Thalassemia Free Survival and Minimal Regimen Related Toxicity in 50 Consecutive Transplants of High Risk Beta Thalassemia Pediatric Patients Using Myelablative Therapy with Intravenous Busulphan.. Blood. 112(11). 3266–3266.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ramdane Belhocine Breakdown of academic impact, for papers by Victoria Gutgarts Breakdown of academic impact, for papers by Ally Speight Breakdown of academic impact, for papers by Sara Varea Breakdown of academic impact, for papers by Keith Sibson Breakdown of academic impact, for papers by A Urbano Ispizua Breakdown of academic impact, for papers by Caitrin Fretham Breakdown of academic impact, for papers by Mirjam Fechter Breakdown of academic impact, for papers by Machiko Kusuda Breakdown of academic impact, for papers by Zefarina Zulkafli